ArticlePloS one2013
A fourteen gene GBM prognostic signature identifies association of immune response pathway and mesenchymal subtype with high risk group.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- mRNA markers for survival prediction in glioblastoma multiforme patients: a systematic review with bioinformatic analyses.BMC cancer · 2024Pooled it
- Exploring the prognostic value and biological pathways of transcriptomics and radiomics patterns in glioblastoma multiforme.Heliyon · 2024Article
- Development and validation of an inflammatory response-related prognostic model and immune infiltration analysis in glioblastoma.Annals of translational medicine · 2023Article
- Article
- Neuroinflammation and immunoregulation in glioblastoma and brain metastases: Recent developments in imaging approaches.Clinical and experimental immunology · 2021Review
- Regulatory Network of PD1 Signaling Is Associated with Prognosis in Glioblastoma Multiforme.Cancer research · 2021Article
- PathCNN: interpretable convolutional neural networks for survival prediction and pathway analysis applied to glioblastoma.Bioinformatics (Oxford, England) · 2021Article
- Neuroinflammation: A Signature or a Cause of Epilepsy?International journal of molecular sciences · 2021Review
- Molecular subtyping of glioblastoma based on immune-related genes for prognosis.Scientific reports · 2020Article
- Development and validation of an immune prognostic signature for ovarian carcinoma.Cancer reports (Hoboken, N.J.) · 2020Article
- Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma.Oncoimmunology · 2020Article
- TGFβ1-induced beta-site APP-cleaving enzyme 2 upregulation promotes tumorigenesis through the NF-κB signalling pathway in human gliomas.Molecular oncology · 2020Article
- Screening and authentication of molecular markers in malignant glioblastoma based on gene expression profiles.Oncology letters · 2019Article
- Microarray gene profiling analysis of glioblastoma cell line U87 reveals suppression of theArchives of medical science : AMS · 2019Article
- RelB acts as a molecular switch driving chronic inflammation in glioblastoma multiforme.Oncogenesis · 2019Article
- TP53 gain-of-function mutation promotes inflammation in glioblastoma.Cell death and differentiation · 2019Article
- A Multi-Cohort and Multi-Omics Meta-Analysis Framework to Identify Network-Based Gene Signatures.Frontiers in genetics · 2019Article
- A 6-Gene Risk Signature Predicts Survival of Glioblastoma Multiforme.BioMed research international · 2019Article
- Article
- An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme.Molecular neurobiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent research on glioblastoma (GBM) has focused on deducing gene signatures predicting prognosis. The present study evaluated the mRNA expression of selected genes and correlated with outcome to arrive at a prognostic gene signature.
methodsPatients with GBM (n = 123) were prospectively recruited, treated with a uniform protocol and followed up. Expression of 175 genes in GBM tissue was determined using qRT-PCR. A supervised principal component analysis followed by derivation of gene signature was performed. Independent validation of the signature was done using TCGA data. Gene Ontology and KEGG pathway analysis was carried out among patients from TCGA cohort.
resultsA 14 gene signature was identified that predicted outcome in GBM. A weighted gene (WG) score was found to be an independent predictor of survival in multivariate analysis in the present cohort (HR = 2.507; B = 0.919; p<0.001) and in TCGA cohort. Risk stratification by standardized WG score classified patients into low and high risk predicting survival both in our cohort (p = <0.001) and TCGA cohort (p = 0.001). Pathway analysis using the most differentially regulated genes (n = 76) between the low and high risk groups revealed association of activated inflammatory/immune response pathways and mesenchymal subtype in the high risk group.
conclusionWe have identified a 14 gene expression signature that can predict survival in GBM patients. A network analysis revealed activation of inflammatory response pathway specifically in high risk group. These findings may have implications in understanding of gliomagenesis, development of targeted therapies and selection of high risk cancer patients for alternate adjuvant therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.